WCLC Updates in Immunotherapy for NSCLC

EP: 1.WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC

EP: 2.WCLC Updates on the Emergence of ADCs in NSCLC

Now Viewing

EP: 3.WCLC Updates in Immunotherapy for NSCLC

EP: 4.WCLC Updates in Neoadjuvant Therapy for NSCLC

EP: 5.WCLC Updates in Locally Advanced NSCLC

EP: 6.WCLC Updates in Small Cell Lung Cancer

Data from the following clinical trials are discussed:

• OA01.06 - Randomized Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR-Mutant NSCLC
• PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
• OA01.03- Clinical Benefits of First-line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC